62466-11-9

Basic information

• Product Name: Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI)
• Synonyms: Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI);2-bromo-1-(3-methyl-2-thienyl)ethanone
• CAS NO: 62466-11-9
• Molecular Formula: C7H7BrOS
• Molecular Weight: 219.09888
• Product Categories: ACETYLHALIDE
• Mol File: 62466-11-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 282.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.566±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI)(62466-11-9)
• EPA Substance Registry System: Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI)(62466-11-9)

Safety Data

• Hazardous Substances Data: 62466-11-9(Hazardous Substances Data)

Usage

General Description

Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI) is a chemical compound with the formula C7H7BrOS. It is commonly known as 2-bromo-3-methylthiophene-2-carbaldehyde and is a yellow liquid with a strong, pungent odor. It is used in the synthesis of pharmaceuticals and agrochemicals, as well as in the manufacturing of other chemical compounds. Ethanone, 2-bromo-1-(3-methyl-2-thienyl)- (9CI) is a highly reactive and potent chemical and should be handled with caution and in accordance with proper safety procedures and regulations.

Upstream product

• 13679-72-6 2-acetyl-3-methylthiophene 

Downstream Products

• 145084-77-1 1,3-Dihydro-1-(3-methyl-2-thenoyl)methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 145084-76-0 3-Amino-1-[2-(3-methyl-thiophen-2-yl)-2-oxo-ethyl]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 145084-78-2 1-[2-(3-Methyl-thiophen-2-yl)-2-oxo-ethyl]-5-phenyl-1H-benzo[e][1,4]diazepine-2,3-dione 3-oxime 

Relevant articles and documents

Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides

Compounds of formula (I): R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.